Inhomogeneous modification of cardiac electrophysiological properties due to Flecainide administration

Andreu M. Climent, M. S. Guillem, P. Lee, C. Bollensdorff, F. Atienza, M. E. Fernández-Santos, R. Sanz-Ruiz, P. L. Sánchez, F. Fernández-Avilés

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Abstract

    Brugada syndrome is characterized by a genetic mutation that leads to a reduction in sodium inward current in phase 0 of the cardiac action potential. However, electrophysiological abnormalities that underlie the phenotypical presentation of this disease remain unclear. The objective of this study was to characterize the spatial electrophysiological changes produced by a reduction in sodium current. Epicardial transmembrane voltage optical maps of 10 Wistar rat hearts isolated and perfused in a Langendorff system were analyzed. For each heart, mean transmembrane action potential duration (APD50) and action potential up-stroke rise time (RT) were measured in the right ventricle (RV) right ventricular outflow tract (RVOT) and left ventricle (LV). Measurements were obtained at baseline and after injection of Flecainide 10uM, a potent sodium channel blocker. Flecainide injection produced a significant increase in APD duration and in the RT at each region with respect to basal conditions. However, the increase in the duration of the APD was higher in the RV compared to the LV (17.34 ± 6.67ms vs. 7.09 ± 6.39ms, p <.01). This increase inverted the APD gradient between RV and LV. By contrast, the increase in RT was significantly higher in the LV than in the RV (3.37 ± 1.84 vs. 2.80 ± 2.11ms, p <0.05). According to our results, Flecainide leads to inhomogeneous modification of electrophysiological properties of the heart and may therefore produce heterogeneities likely to initiate and/or maintain a fibrillatory process.

    Original languageEnglish
    Title of host publicationIFMBE Proceedings
    Pages423-426
    Number of pages4
    Volume41
    DOIs
    Publication statusPublished - 2 Jan 2014
    Event13th Mediterranean Conference on Medical and Biological Engineering and Computing 2013, MEDICON 2013 - Seville, Spain
    Duration: 25 Sep 201328 Sep 2013

    Other

    Other13th Mediterranean Conference on Medical and Biological Engineering and Computing 2013, MEDICON 2013
    CountrySpain
    CitySeville
    Period25/9/1328/9/13

    Fingerprint

    pamidronate
    Flecainide
    Sodium
    Sodium Channel Blockers
    Rats
    Electric potential

    Keywords

    • Brugada sindrome
    • Flecainide
    • Isolated langendorff
    • Optical mapping

    ASJC Scopus subject areas

    • Biomedical Engineering
    • Bioengineering

    Cite this

    Climent, A. M., Guillem, M. S., Lee, P., Bollensdorff, C., Atienza, F., Fernández-Santos, M. E., ... Fernández-Avilés, F. (2014). Inhomogeneous modification of cardiac electrophysiological properties due to Flecainide administration. In IFMBE Proceedings (Vol. 41, pp. 423-426) https://doi.org/10.1007/978-3-319-00846-2_105

    Inhomogeneous modification of cardiac electrophysiological properties due to Flecainide administration. / Climent, Andreu M.; Guillem, M. S.; Lee, P.; Bollensdorff, C.; Atienza, F.; Fernández-Santos, M. E.; Sanz-Ruiz, R.; Sánchez, P. L.; Fernández-Avilés, F.

    IFMBE Proceedings. Vol. 41 2014. p. 423-426.

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Climent, AM, Guillem, MS, Lee, P, Bollensdorff, C, Atienza, F, Fernández-Santos, ME, Sanz-Ruiz, R, Sánchez, PL & Fernández-Avilés, F 2014, Inhomogeneous modification of cardiac electrophysiological properties due to Flecainide administration. in IFMBE Proceedings. vol. 41, pp. 423-426, 13th Mediterranean Conference on Medical and Biological Engineering and Computing 2013, MEDICON 2013, Seville, Spain, 25/9/13. https://doi.org/10.1007/978-3-319-00846-2_105
    Climent AM, Guillem MS, Lee P, Bollensdorff C, Atienza F, Fernández-Santos ME et al. Inhomogeneous modification of cardiac electrophysiological properties due to Flecainide administration. In IFMBE Proceedings. Vol. 41. 2014. p. 423-426 https://doi.org/10.1007/978-3-319-00846-2_105
    Climent, Andreu M. ; Guillem, M. S. ; Lee, P. ; Bollensdorff, C. ; Atienza, F. ; Fernández-Santos, M. E. ; Sanz-Ruiz, R. ; Sánchez, P. L. ; Fernández-Avilés, F. / Inhomogeneous modification of cardiac electrophysiological properties due to Flecainide administration. IFMBE Proceedings. Vol. 41 2014. pp. 423-426
    @inbook{df1b18a79ad340489ee279558b91d7a3,
    title = "Inhomogeneous modification of cardiac electrophysiological properties due to Flecainide administration",
    abstract = "Brugada syndrome is characterized by a genetic mutation that leads to a reduction in sodium inward current in phase 0 of the cardiac action potential. However, electrophysiological abnormalities that underlie the phenotypical presentation of this disease remain unclear. The objective of this study was to characterize the spatial electrophysiological changes produced by a reduction in sodium current. Epicardial transmembrane voltage optical maps of 10 Wistar rat hearts isolated and perfused in a Langendorff system were analyzed. For each heart, mean transmembrane action potential duration (APD50) and action potential up-stroke rise time (RT) were measured in the right ventricle (RV) right ventricular outflow tract (RVOT) and left ventricle (LV). Measurements were obtained at baseline and after injection of Flecainide 10uM, a potent sodium channel blocker. Flecainide injection produced a significant increase in APD duration and in the RT at each region with respect to basal conditions. However, the increase in the duration of the APD was higher in the RV compared to the LV (17.34 ± 6.67ms vs. 7.09 ± 6.39ms, p <.01). This increase inverted the APD gradient between RV and LV. By contrast, the increase in RT was significantly higher in the LV than in the RV (3.37 ± 1.84 vs. 2.80 ± 2.11ms, p <0.05). According to our results, Flecainide leads to inhomogeneous modification of electrophysiological properties of the heart and may therefore produce heterogeneities likely to initiate and/or maintain a fibrillatory process.",
    keywords = "Brugada sindrome, Flecainide, Isolated langendorff, Optical mapping",
    author = "Climent, {Andreu M.} and Guillem, {M. S.} and P. Lee and C. Bollensdorff and F. Atienza and Fern{\'a}ndez-Santos, {M. E.} and R. Sanz-Ruiz and S{\'a}nchez, {P. L.} and F. Fern{\'a}ndez-Avil{\'e}s",
    year = "2014",
    month = "1",
    day = "2",
    doi = "10.1007/978-3-319-00846-2_105",
    language = "English",
    isbn = "9783319008455",
    volume = "41",
    pages = "423--426",
    booktitle = "IFMBE Proceedings",

    }

    TY - CHAP

    T1 - Inhomogeneous modification of cardiac electrophysiological properties due to Flecainide administration

    AU - Climent, Andreu M.

    AU - Guillem, M. S.

    AU - Lee, P.

    AU - Bollensdorff, C.

    AU - Atienza, F.

    AU - Fernández-Santos, M. E.

    AU - Sanz-Ruiz, R.

    AU - Sánchez, P. L.

    AU - Fernández-Avilés, F.

    PY - 2014/1/2

    Y1 - 2014/1/2

    N2 - Brugada syndrome is characterized by a genetic mutation that leads to a reduction in sodium inward current in phase 0 of the cardiac action potential. However, electrophysiological abnormalities that underlie the phenotypical presentation of this disease remain unclear. The objective of this study was to characterize the spatial electrophysiological changes produced by a reduction in sodium current. Epicardial transmembrane voltage optical maps of 10 Wistar rat hearts isolated and perfused in a Langendorff system were analyzed. For each heart, mean transmembrane action potential duration (APD50) and action potential up-stroke rise time (RT) were measured in the right ventricle (RV) right ventricular outflow tract (RVOT) and left ventricle (LV). Measurements were obtained at baseline and after injection of Flecainide 10uM, a potent sodium channel blocker. Flecainide injection produced a significant increase in APD duration and in the RT at each region with respect to basal conditions. However, the increase in the duration of the APD was higher in the RV compared to the LV (17.34 ± 6.67ms vs. 7.09 ± 6.39ms, p <.01). This increase inverted the APD gradient between RV and LV. By contrast, the increase in RT was significantly higher in the LV than in the RV (3.37 ± 1.84 vs. 2.80 ± 2.11ms, p <0.05). According to our results, Flecainide leads to inhomogeneous modification of electrophysiological properties of the heart and may therefore produce heterogeneities likely to initiate and/or maintain a fibrillatory process.

    AB - Brugada syndrome is characterized by a genetic mutation that leads to a reduction in sodium inward current in phase 0 of the cardiac action potential. However, electrophysiological abnormalities that underlie the phenotypical presentation of this disease remain unclear. The objective of this study was to characterize the spatial electrophysiological changes produced by a reduction in sodium current. Epicardial transmembrane voltage optical maps of 10 Wistar rat hearts isolated and perfused in a Langendorff system were analyzed. For each heart, mean transmembrane action potential duration (APD50) and action potential up-stroke rise time (RT) were measured in the right ventricle (RV) right ventricular outflow tract (RVOT) and left ventricle (LV). Measurements were obtained at baseline and after injection of Flecainide 10uM, a potent sodium channel blocker. Flecainide injection produced a significant increase in APD duration and in the RT at each region with respect to basal conditions. However, the increase in the duration of the APD was higher in the RV compared to the LV (17.34 ± 6.67ms vs. 7.09 ± 6.39ms, p <.01). This increase inverted the APD gradient between RV and LV. By contrast, the increase in RT was significantly higher in the LV than in the RV (3.37 ± 1.84 vs. 2.80 ± 2.11ms, p <0.05). According to our results, Flecainide leads to inhomogeneous modification of electrophysiological properties of the heart and may therefore produce heterogeneities likely to initiate and/or maintain a fibrillatory process.

    KW - Brugada sindrome

    KW - Flecainide

    KW - Isolated langendorff

    KW - Optical mapping

    UR - http://www.scopus.com/inward/record.url?scp=84891296950&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84891296950&partnerID=8YFLogxK

    U2 - 10.1007/978-3-319-00846-2_105

    DO - 10.1007/978-3-319-00846-2_105

    M3 - Chapter

    SN - 9783319008455

    VL - 41

    SP - 423

    EP - 426

    BT - IFMBE Proceedings

    ER -